Drug Reimportation Rejected Again

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WASHINGTON-A second Secretary of Health and Human Services (HHS), Tommy G. Thompson, has refused to allow the reimporting of US-made prescription drugs back into the country. Former HHS Secretary Donna E. Shalala made the same determination last December.

WASHINGTON—A second Secretary of Health and Human Services (HHS), Tommy G. Thompson, has refused to allow the reimporting of US-made prescription drugs back into the country. Former HHS Secretary Donna E. Shalala made the same determination last December.

Under the Medicine Equity and Drug Safety (MEDS) Act, signed into law last year, US-made prescription drugs exported to certain foreign nations could be reimported for sale to US consumers. US medications sell for less abroad, and the law’s intent was that reimported drugs would be sold at below normal prices.

MEDS included a provision that required the HHS Secretary to determine that, if reimportation occurred, the United States could maintain adequate safety and prices could be expected to be reduced. Mr. Thompson found that would not be the case.

"Opening our borders as required under this program would increase the likelihood that the shelves of pharmacies across the nation would include counterfeit drugs, cheap foreign copies of FDA-approved drugs, expired drugs, contaminated drugs, and drugs stored under inappropriate and unsafe conditions," the Secretary said in a letter to Sen. James Jeffords (I-Vt).

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content